Trial Watch

Clinical trials covered by The Clinical Lighthouse, ranked by methodological rigor and ordered by most recent.

193 trials indexed
Prehospital Whole Blood Does Not Reduce 30-Day Mortality Over Components
PIVOTAL TRIAL · LAST 30 DAYS
Randomized Controlled Trial New England Journal of Medicine

Prehospital Whole Blood Does Not Reduce 30-Day Mortality Over Components

A large-scale trial found no significant difference in 30-day mortality between prehospital whole blood and component transfusions for trauma…

May 20, 2026 Read the trial →
Obinutuzumab Shows High Efficacy in Active Systemic Lupus Erythematosus Randomized Controlled Trial
New England Journal of Medicine

Obinutuzumab Shows High Efficacy in Active Systemic Lupus Erythematosus

A phase 3 trial shows the anti-CD20 antibody obinutuzumab significantly improves clinical responses and reduces flares in active lupus.

March 16, 2026
Pimicotinib Yields 54% Response in Tenosynovial Giant Cell Tumors Randomized Controlled Trial
The Lancet

Pimicotinib Yields 54% Response in Tenosynovial Giant Cell Tumors

The selective inhibitor pimicotinib demonstrates high efficacy for unresectable joint tumors while avoiding severe hepatotoxicity.

March 15, 2026
Zorevunersen Cuts Convulsive Seizures in Children With Dravet Syndrome Randomized Controlled Trial
New England Journal of Medicine

Zorevunersen Cuts Convulsive Seizures in Children With Dravet Syndrome

The investigational antisense therapy reduced convulsive-seizure frequency by up to 90.91% and improved adaptive behavior over 36 months.

March 15, 2026
Finerenone Reduces Albuminuria in Type 1 Diabetes and CKD Randomized Controlled Trial
New England Journal of Medicine

Finerenone Reduces Albuminuria in Type 1 Diabetes and CKD

A phase 3 trial shows the mineralocorticoid receptor antagonist finerenone safely lowers albuminuria in adults with type 1 diabetes.

March 15, 2026
Baxdrostat Reduces 24-Hour Blood Pressure in Resistant Hypertension Randomized Controlled Trial
The Lancet

Baxdrostat Reduces 24-Hour Blood Pressure in Resistant Hypertension

A phase 3 trial shows the selective aldosterone synthase inhibitor baxdrostat reduces systolic blood pressure by 14 mm Hg versus placebo.

March 15, 2026
Neoadjuvant GOLP Doubles Event-Free Survival in Cholangiocarcinoma Randomized Controlled Trial
New England Journal of Medicine

Neoadjuvant GOLP Doubles Event-Free Survival in Cholangiocarcinoma

Administering the GOLP regimen before surgery extends median event-free survival to 18 months in high-risk intrahepatic cholangiocarcinoma.

March 15, 2026
Social Skills Training Modulates Local Connectivity in the Autistic Social Brain Non-Randomized Controlled Trial
Frontiers in Psychiatry

Social Skills Training Modulates Local Connectivity in the Autistic Social Brain

A 14-week intervention reduces regional homogeneity in the medial frontal gyrus, correlating with improved social responsiveness scores.

March 15, 2026
Hybrid Dialectical Behavior Therapy Reduces Suicidal Ideation in Adolescents Randomized Controlled Trial
Frontiers in Psychiatry

Hybrid Dialectical Behavior Therapy Reduces Suicidal Ideation in Adolescents

A year-long trial shows combining online and offline DBT improves emotional regulation and depressive symptoms in self-injuring youth.

March 14, 2026
Apixaban Reduces Bleeding Risk Versus Rivaroxaban in Venous Thromboembolism Randomized Controlled Trial
New England Journal of Medicine

Apixaban Reduces Bleeding Risk Versus Rivaroxaban in Venous Thromboembolism

In a randomized trial of 2,760 patients, apixaban resulted in a 3.3% bleeding rate compared to 7.1% for rivaroxaban over three months.

March 14, 2026
Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers Randomized Controlled Trial
New England Journal of Medicine

Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers

A phase 3 trial shows romiplostim maintains platelet counts, allowing patients to receive full oxaliplatin-based chemotherapy doses.

March 14, 2026
Inhaled Treprostinil Slows FVC Decline in Idiopathic Pulmonary Fibrosis Randomized Controlled Trial
New England Journal of Medicine

Inhaled Treprostinil Slows FVC Decline in Idiopathic Pulmonary Fibrosis

A phase 3 trial shows inhaled treprostinil preserves forced vital capacity and reduces clinical worsening over 52 weeks versus placebo.

March 14, 2026
Clozapine Increases Response After One Failed Antipsychotic in Early Psychosis Randomized Controlled Trial
JAMA Psychiatry

Clozapine Increases Response After One Failed Antipsychotic in Early Psychosis

A sequential trial reveals that switching to clozapine after a single failed antipsychotic yields a 62.5% response rate in early psychosis.

March 13, 2026
Trial: Higher Bupivacaine Doses Do Not Improve Nerve Block Headache Relief Randomized Controlled Trial
Annals of Emergency Medicine

Trial: Higher Bupivacaine Doses Do Not Improve Nerve Block Headache Relief

A randomized trial finds that low-dose, unilateral sphenopalatine ganglion blocks are as effective as higher doses for acute headaches

March 12, 2026